Plain-English translation of NCT05627232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing two different combination approaches using — a newer type of medication — paired with an existing chemotherapy drug called CPX-351 for people with acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. The study wants to find the right dose of each medication and see if these combinations can help patients. You would be one of about 24 people in this research.
Acute myeloid leukemia that comes back or doesn't respond to initial treatment is very difficult to cure with standard therapy alone. This medication combination may work differently than treatments used before, and doctors want to understand whether pairing it with chemotherapy might help patients who have limited options.
You likely qualify if…
You likely don't qualify if…
You would come to Thomas Jefferson University for screening visits where doctors will confirm your diagnosis with blood and bone marrow tests. Then you'll receive one of the two medication combinations: either the medication by mouth for several days combined with intravenous chemotherapy on days 1, 3, and 5, or a pre-treatment pill followed by the same chemotherapy schedule. After treatment ends, you'll have follow-up visits at 3 months, 6 months, and 1 year to check how you're doing.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States